There are over a million new cases of colorectal cancer (CRC) being diagnosed each year, worldwide. CRC is known to be the third most frequent malignancy and the fourth most frequent cause of cancer-related deaths. 1 Development of CRC) is often attributed to a combination of genetic predisposition and environmental factors. Up to 25% of cases are found to be hereditary, and the remaining cases are due to environmental factors. 2,3 Inherited syndromes include familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancers (HNPCC) and other types of tumour with a familial history. 2 Environmental factors that may have an effect are diet low in fibre and high in fat and red meat, heavy alcohol consumption, a sedentary occupation, low physical activity, obesity and cigarette smoking. 4
Most CRCs are thought to develop from adenomatous polyps (growths) arising from the lining of the intestine, and evidence is suggestive that adenomas are possibly present for several years before malignancy progresses. The number and size of adenomas, in addition to their histological type accompanied by the presence of epithelial dysplasia, is thought to affect the risk of development to CRC. 5, 6 Regardless of diagnostic and therapeutic advances, tumour recurrence and metastasis are two critical factors effecting the survival rates of patients with CRC. 7 Nearly 50% of patients with CRC will develop metastases, either at presentation or during follow-up. 8 
Pitfalls of conventional treatment methods for CRC
Common treatment modalities for CRC include the following: chemotherapy, radiation therapy (RT), targeted therapy and surgery. [9] [10] [11] The treatment of choice is solely dependent on the stage of the disease. At present, the primary treatment method is surgical resection. In early stages of the disease (stage 0 or I), surgical excision is used without the need for further treatment options; however, cancer recurrence is common as it is estimated that one-half of patients will experience a recurrence in the first 3 years post surgery. For Stages I-III, the 'gold standard' therapeutic choice is colon cancer resection along with a proper lymphadenectomy. 12 Patients with stage IV disease require chemotherapy or targeted therapies combined with surgery. 10 However, to date, chemotherapy only results in objective responses in 30% of cases, 13 and if metastases has occurred, chemotherapy may not be a cure, but does help in improving prognosis, tumour shrinkage and relief of symptoms. 10 RT is usually useful to treat Stage II or Stage III CRC and may shrink unresectable tumours so that they can be surgically removed. 11 RT can also be used to help control spread to other parts of the body in patients that are not healthy enough for surgery. 14 Unfortunately, RT has side effects including nausea, stool leakage, fatigue, sexual problems, skin irritation, rectal irritation and diarrhea. 15 In addition, CRC survivors are at increased risk of second primary cancers of the colon and rectum, as well as other cancer sites. 16 
Resistance to treatment and tumour metastases
The decrease in efficacy of current therapies is due to patients developing resistance. Resistance to therapies occurs in almost all patients with CRC. 9 Several studies have shown drug resistance attributed to mutations and the corresponding deregulated signalling pathways in colon cancer patients. These mutations occur in a group of oncogenes that result in poor responses to targeted therapies. 17 Failure of response to therapeutic drugs occurs in 90% of metastatic CRCs and is attributed to resistance related to an increased aerobic glycolysis, fatty acid synthesis and glutamine metabolism, which consequently leads to a decreased drug-induced apoptosis. Additionally, drug efflux transporter proteins are found to be overexpressed which leads to decreased delivery of the drug to cancer cells, by reduced uptake by the cell or by changes in enzymes involved in metabolism, as shown in Figure 1 . 7, 18 RT is often used prior to, or following, surgical resection and often combined with chemotherapy, to reduce the risk of tumour recurrence. A proportion of tumours initially respond well to radiation, but a large proportion of patients experience resistance to RT. 19 When cancer cells exposed to RT prompted DNA damage, the kinase Ataxia Telangiectasia Mutated (ATM) is triggered to stimulate DNA repair pathways. In addition, ATM also controls the pro-survival and radio-resistance pathways in exposed cells. 20 The anti-apoptotic factors phosphatase of regenerating liver-3 (PRL-3) and survivin have also been identified as resistance factors in RT, as these factors have been shown to correlate with advanced CRC, liver and lymph node metastases, high risk of recurrences and shorter patient survival. 21 In addition to therapeutic resistance, metastasis of CRC is another concern. Mutations in the TGF-β, PIK3CA and TP53 genes are responsible for clonal expansion of a carcinoma, as well cellular potential for invasiveness and metastasis. Metastatic potential is also acquired rapidly by these cells and frequently occurs in the liver. Although it is known that a primary colorectal tumour occurs due to mutations, the molecular basis for the advance of metastatic CRC remains largely unknown. 22 Figure 1 . Illustration of mechanisms of tumour cell resistance to therapy. Decreased uptake of chemotherapeutic drugs caused by drug efflux proteins in the cell membrane and changes in drug metabolism. Other metabolic associated resistance occurs through increased aerobic glycolysis, fatty acid synthesis and glutamine metabolism, which results in decreased drug-induced apoptosis.
Another factor that plays an important role in resistance to therapy, as well as tumour metastasis, in CRC is the presence of cancer stem cells (CSCs). CSCs undergo a slow rate of cycling which enhances resistance to treatment (chemotherapy and radiotherapy) and increases the likelihood of tumour recurrence. Additionally, CSCs have the ability to initiate new tumours which may be of important in metastatic colonization. 7
The controversial CSCs
Origin Normal adult stem cells (ASCs) have the potential for unlimited replicative abilities and self-renewal capacity. This lead to the hypothesis that stem cells may be the origin for many cancers. 23 The stem cell hypothesis consists of two related, but separate, components: (1) concerns the cellular origin of tumours and (2) that tumours are driven by cellular constituents that display 'stem cell' properties. 24 This subpopulation of cells are presumed to be a result of somatic mutations of a normal ASC, giving it a proliferative advantage, resulting in generation of clonal outgrowth in the tissue ultimately leading to the formation of a neoplasm. 25 CSCs share the same characteristics as those of normal stem cells, which include ability for self-renewal and differentiation. 26 CSCs have the ability to reconstitute tumours, and proliferate slowly, for an extended period of time. 27 The combination of these mutation/proliferation mechanisms and the tumour microenvironment leads to the different stages of cancer progression. 28 CSCs are also thought to be the root of resistance to conventional treatment methods such as chemotherapy and radiotherapy. 29 Their resistance is a result of their ability to better repair intracellular damage (i.e. DNA and protein damage), and they can effectively quench intracellular reactive oxygen species (ROS), reducing the amount of damage that they incur when under stressful conditions. In addition, CSCs have been identified as the cells responsible for metastases of the primary tumour, survival in the bloodstream and colonization in distant organs. 30 
Evidence of CSCs
The connection between cancer and CSCs was first discovered in the 19th century by histological examination of tumour and embryonic tissue that displayed similarities. 31 A number of studies followed leading up to a discovery in 1960 by Nowell 32 a Hungerford of the Philadelphia (Ph) chromosome and its association with chronic myeloid leukaemia (CML). The succeeding demonstration of the Ph chromosome in all the major non-lymphoid lineages of blood cells from patients with chronic phase CML confirmed Dameshek's prophecy of a possible common origin of the CML clone from a transformed, but still multipotent, haematopoietic stem cell. 15, 30 Another study investigating multiple myeloma also presented that only a small subgroup of cancer cells were capable of extensive proliferation. 33 In 2003, the CSC concept was applied the first time to solid tumours by Clarke et al. These researchers identified a subpopulation of specific marker expressing breast CSCs as the only tumour-initiating population that was able to produce new tumours by serial passaging in immunodeficient mice. 34 Since, CSCs have been isolated from various cancers, including breast cancer, 35 prostate cancer, 36 pancreatic cancer, 37 head and neck cancer, 38 lung cancer, 39 hepatocellular carcinoma, 40 and renal CSCs. 41 
Identifying CRC stem cells
CSCs are identified by the expression of specific markers, and several markers have been proposed in CRC. 42 Colon cancer stem cells (CCSCs) were first identified in 2007 by two different research groups using CD133. 43, 44 The study revealed that only a small subset of CD133+ cells was capable of initiating tumour growth, while negative cells were not, and although normal colon cells expressed CD133, they did so at lower numbers. 45 Similarly, CD44positive cells showed a higher capacity to form clones in vitro and to generate xenograft tumours in immunodeficient mice. 46 Levin et al. 47 exhibited that CD166 marks the stem cell function in the intestinal crypt in both mice and humans. This is suggestive of CD166-expressing cells importance in the establishment and maintenance of the endogenous intestinal stem cell niche. The three above-mentioned cell surface markers are the main markers currently being associated with CRC stem cells. Although findings from studies using these markers separately are controversial, their combined analysis may be effective in identification of low, intermediate and high-risk cases of CRC. 48 Additional markers include those that were found to be associated with stemness characteristics. 45 A summary of the potential CRC stem cell markers and their functions are given in Table 1 .
Current eradication methods of CSCs
Failure to eliminate CSCs is believed to be an underlying cause for resistance to conventional therapy and recurrence of malignancy. In addition, continued use of conventional chemotherapeutics is associated with added toxicities, which can be fatal. It is, therefore, necessary to implement therapeutic strategies that specifically target colon CSCs. Yu et al. 57 studied the effects of combining a conventional colon cancer chemotherapeutic regimen with curcumin and found that it could be effective in reducing/ eliminating the CSCs. The HOXA5 protein is an important repressor of intestinal stem cell fate in vivo. In colon cancer, the HOXA5 protein is downregulated, and its reexpression results in loss of the CSC phenotype, averting tumour advancement and metastasis. Retinoids can be used to trigger tumour regression by HOXA5 induction and offer a means to treat colon cancer by eradicating CSCs. 58 Other forms of CSC-targeted therapies include monoclonal antibodies, blockage of self-renewal pathways by small molecular inhibitors, and induction of differentiation and the disruption of epithelial-mesenchymal transition (EMT). Resistance of CCSCs to the drug oxaliplatin can be overcome by sensitizing cells with an interleukin-4 blocking antibody which effects their stemness and drug resistant properties. Other studies have testified the efficacy of anti-EREG antibody (epiregulin, epidermal growth factor family) against tumour metastasis in a metastatic model tested suggesting that the anti-EREG antibody is successful in the early stage of cancer expansion when cancers are rich in CSCs. 7 Targeting and inhibiting the small molecules involved in stem cell pathways can also be effective treatment strategies. An example is the Wnt proteins, which are cysteinerich molecules, that play a critical role in the development of various organisms and a vital role in embryogenesis and propagation, survival and differentiation of haematopoietic stem cells. 59 Defects in the Wnt/β-catenin signalling pathway have been implicated in several types of human cancers, including ovarian colon cancer, and also play a critical role in CSCs. Stem cells with high levels of Wnt/βcatenin signalling display greater tumourigenic potential and, therefore, targeting the Wnt/β-catenin signalling pathway could be a potential treatment for CCSCs. 60 The gene p53 induces cell-cycle arrest, senescence or apoptosis preventing the build-up of genetic mutations within cells undergoing stress. The gene is mutated in several human cancers, including colon cancer, and cancer progression is reliant on loss of WT p53 function. 61, 62 Restoration of the WT p53 function is essential for the efficacy of chemotherapy and radiation, thus p53 restoration compounds may be used to enhance chemo-and radiosensitivity. 63 p53 also plays a role in the suppression of factors involved in the maintenance of self-renewal of mesenchymal stem cells (MSCs). Growing evidence supports that deregulation of the functions of embryonic stem cells (ESCs), which could be due to p53 mutations, and ASCs may lead to developmental abnormalities, alterations in adult tissue maintenance and generation of CSCs. 64 Restoration of WT p53 gene activity could be a promising tumour-specific regimen for targeting the CSC population. 61 Targeted agents, as shown in Figure 2 , have been established and have demonstrated improved outcome in metastatic CRC patients, in combination with chemotherapy. 10 However, although these therapies have shown promise, anti-angiogenic drugs have proven to be toxic and affect multiple organs, and cancers have shown to become resistant to small-molecule inhibitors. None of the above-mentioned targeted therapies have shown to be a cure. 65, 66 
Photodynamic therapy an emerging treatment modality
Photodynamic therapy (PDT) is a promising method used for the control of a variety of cancers. 67 PDT is a harmonized process which first requires the exposure of the cancer tissue to a photosensitizer (PS), administered either topically or intravenously, depending on the location of the targeted tissues. 68 A PS is a molecule that is taken up and localizes in the target cell and/or tissue and can only be activated by light. 69 Activation of a PS is achieved through exposure to laser irradiation at a specific wavelength. Once Table 1 . Cancer stem cell markers in colorectal cancer.
Marker
Function Reference
CD133
Transmembrane glycoprotein Shmelkov et al. 49 
CD 29
Integrin that mediates cell-ECM adhesion and is involved in homing to sites of inflammation photons are absorbed by a PS, it is excited and stimulated from the ground state to a higher level of energy, a singlet state. 70 Alternatively, the molecule may convert to the triplet state through a mechanism called intersystem crossing, which results in a change in the spin of an electron. In this triplet state, the PS reacts with molecular oxygen and gives rise to free ROS that can destroy cancer tissue 71 (Figure 3 ). Efficiency of PDT depends on the production of ROS in the cell that are generated through two types of photoreactions. In Type I, the PS reacts with biomolecules, through a hydrogen atom (electron) transfer, to form radicals which react with molecular oxygen to generate ROS, subsequently leading to the production of oxidative stress and ultimately cell death. In the second reaction type (Type II), energy is transferred directly to oxygen in the cell to form a singlet oxygen (a subset of ROS) which then oxidizes various substrates resulting in cell death. 72 A major advantage of using PDT is that it achieves selective cell destruction and minimizes damage to adjacent healthy structures. PSs are taken up by all cells; however, they tend to preferentially localize in diseased tissue and remain in diseased tissue for a longer period of time due to the enhanced permeability retention (EPR) effect. 73 Consequently, it is vital to ensure PS activation only occurs once the proportion of PS in diseased tissue is greater than that present in healthy tissue. 74 Other advantages of PDT over conventional treatment options include being a minimally invasive technique, lowering morbidity rate, ability to reserve the anatomic and functional integrity of many cells, minimal side effects, selective targeting, and no drug resistance, as well as reduced toxicity which allows for repeated treatment. 75 
Overcoming resistance to PDT of CSCs
CSCs are thought to be resistant to conventional cancer therapies, including PDT, but resistance to PDT depends on a variety of factors. Figure 4 shows examples of overcoming resistance to PDT.
Subcellular localization of PSs
PS uptake and localization play a critical role in the effectiveness of PDT in the treatment of cancer. Subcellular localization of photosensitizers in different cellular components may induce various pathways of cell death/damage. Subcellular localization sites of PSs include the plasma membrane, lysosomes, Golgi apparatus, the nucleus and the mitochondria. 76 PSs localizing in lysosomes can lead to cell killing upon illumination, but the relative efficacy is significantly lower when compared to a PS localized in the mitochondria and other organelles. In mitochondria, many PSs cause mitochondrial damage after illumination and subsequently lead to apoptosis of the cell, this is, therefore, the most common type of PSs used. PSs that accumulate in smaller amounts in more than one organelle (colocalization) may be used in combination to enhance the PDT efficacy of the PSs. 77 
PS solubility
Solubility also plays a role as most PSs are hydrophobic. 76 Hydrophobicity and a tendency to aggregate in aqueous environments hinder bioavailability of several PSs. Aggregation reduces increased uptake of photosensitization by the mononuclear phagocytic system (MPS) and decreased uptake by target cells as well as an increased risk of anaphylactic reactions. 78 Sulphonation of PSs can aid in overcoming these issues as it affects the lipophilicity of a drug; henceforth, its cellular uptake and tendency to aggregate in cells may also play a role in the tumour localizing ability of a drug. Phthalocyanine PSs (PCSs) can be tuned for optimal solubility and minimal aggregation by the introduction of substituents in the peripheral positions of the tetraaza isoindole macrocycle, coordination of metal ions with the central atoms, and the addition of axial ligands in the fifth and sixth positions. Another modification could be the conjugation to a nano-particle (NP) which could increase solubility and cellular uptake. Such modifications can tune the water solubility and aggregation of the PCSs, without significantly affecting its photophysical properties. 79 
PS delivery and selectivity
Abundant literature describes the use of NPs as a delivery system of drugs to increase the response to anticancer compounds. 80 A wide variety of organic and inorganic nano-constructs, such as liposomal, micellar, polymeric, silica and gold NPs, have been introduced to deliver high payloads of PS to desired sites, when combined with targeting processes. 81 Advantages of using NPs include lower levels of the PSs used in treatment, increased selectivity, reduced side effects and reduced dark toxicity. In addition, peptide or antibody tags in NP systems can increase selectivity more efficiently and aid in controlling the size of the particle, which can influence better passive targeting through EPR effect and, therefore, increased cellular uptake. 82 
Antibody-mediated specificity
In an effort to increase PS accumulation specificity and reduce unwanted PDT PS and NP side effects, significant effort has been devoted towards the synthesis, and characterization, of bio-conjugates. Synthesis with either NPs or PSs further enhances PDT NP-PS passive drug delivery by actively and specifically targeting tumourous cells with monoclonal antibody (mAb) conjugates. In the case of anticancer-mediated PDT, malignant cells present different types, as well as greater amounts, of many surface antigens. 83 Antibodies against tumour-associated antigens are easily generated, and if correctly attached to a PS drug delivery system, the PS can be directly targeted and absorbed via cell membrane endocytosis into specific tumours and therefore causes targeted cancer cell death upon PDT light activation. 84 
Small-molecule inhibitors
Cells resistant to PDT may express genes that inhibit the transport of the PS into the cell. The main focus has been on P-glycoprotein (P-gp) and adenosine triphosphate (ATP)-binding cassette sub-family G member 2ABCG2 as PDT inhibitors. The expression of P-gp in tumour cells results in a reduction of intracellular drug concentrations and subsequent decrease in cytotoxicity. 85 ABCG2 is an ATP-binding cassette half-transporter overexpressed in cells resistant to several drugs and has been identified in a wide variety of tumours including adenocarcinomas of the digestive tract. 86 As a member of the family of multidrug resistance proteins, it protects cell from exogenous and endogenous toxins through the efflux system. 87 Altering the expression of these proteins by administering blockers in conjunction with PDT, PSs may overcome cellular resistance.
ROS
ROS are the natural by-products of cellular oxidative metabolism. Cells exposed to PDT undergo stress and ROS are created as intermediates, and their cellular levels are controlled by various detoxifying enzymes. 88 Superoxide dismutase (SOD) is a crucial antioxidant enzyme that defends cells against potentially damaging superoxide radicals, like those produced in PDT. In order to overcome the protective effects of SOD, combinations of SOD inhibitors such as; potassium cyanide, chloroformethanol, H 2 O 2 and NaN 3 , administered together with PDT might increase the efficiency of the anticancer treatment. 89, 90 Modified PDT techniques have been developed to overcome reduced oxygen levels, which ultimately reduces the efficacy of PDT in tumour microenvironments, which houses CSCs. Usacheva et al. 91 increased production of ROS using surfactant-polymer NP which also proved effective at eliminating CSCs.
Heat-shock proteins
Heat-shock proteins (HSPs) are reported to provide effective cytoprotection under various stress stimuli. 92 In addition, it regulates inflammatory and immune responses. 93 The most studied being Hsp70 which is overexpressed in cells under heat stress and protect proteins from being damaged. 94 Some PSs used in PDT therapy can induce the expression of HSP70; however, porphyrin-derived PSs have shown to be less effective in the induction of HSP70 expression but leads to redistribution of HSP70 to cell surfaces. HSP70 on the cell surface subsequently facilitates the development of adaptive immunity by providing a specific signal that activates macrophage uptake of apoptotic bodies. Therefore, to increase effectiveness of PDT, combining it with hyperthermic (HPT) treatment could increase the expression of HSP70 and its enhanced surface localization on treated tumour cells. 95 Studies on glioblastoma have shown that the combined HPT and PDT approach is quite effective to treat this type of cancer. 96 Hypoxia PDT-induced hypoxia and inflammation lead to changes in the tumour microenvironment associated with increased expression of angiogenic and pro-survival molecules, including cyclooxygenase-2 (COX-2). 97 COX-2 is an inducible form of the enzyme that catalyzes the first step in the synthesis of prostanoids, which is associated with inflammatory diseases and carcinogenesis. 98 COX-inhibitors have proven success in overcoming tumour immune evasion. It has been proposed that COX-inhibitors sensitize type 1 immune responses by inhibiting M2 macrophages, T regulatory cells and myeloid-derived suppressor cells (MDSC) and enhancing dendritic cells (DC), natural killer (NK) and cytotoxic T-lymphocyte functions. Use of selective COX-2 inhibitors could result in a substantial risk reduction in many cancers including CRC. Findings from the study by Rahman et al. 99 presented the potential benefit of combining COX-2 inhibitors with current cancer treatment regimens to achieve better responses.
PSs applied in photodynamic treatment of colon cancer and CCSCs
Tetrapyrollic photosynthetic drugs such as porphyrins, chlorins and phthalocyanines have shown to be effective in PDT of CRC. 100 Table 2 lists some current PDT studies which utilize different types of PSs for the in vitro treatment of CRC and CCSCs.
Targeted PDT for colon cancer and CCSCs

PS targeting of CRC and CRC stem cells
Although some PSs used in PDT reveal certain tumour selectivity by the EPR effect, they can also accumulate in healthy tissues causing side effects such as phototoxic and photoallergic reactions. 117 To avoid this complication, targeted photodynamic therapy (TPDT) was fashioned to improve PS drug delivery to cancer tissue, and the overall specificity and efficiency of PDT was increased. 100 TPDT can be divided into two mechanisms of action: passive or active targeting. Passive PDT targeting makes use of the PSs drug carrier's physicochemical factors, as well as the morphological and physiological differences between normal and tumour tissue (i.e. EPR effect) to deliver the PS to a target site. 73 Active PDT targeting involves PS drug delivery to a specific tumour site, which is based on a molecular recognition process, using specific ligands or antibodies which bind to overexpressed cancer cell receptors. 100 These two cellular uptake mechanisms have been illustrated in Figure 5 .
Passive targeting of CRC and CRC stem cells
There is a great interest in NPs as drug carriers for selective transporting of PSs to CRC and CCSC cells. 7, 100 Most PS drug delivery systems are optimized with NPs to enhance passive drug uptake, promote solubility and stability and limit non-specific toxicity. 118 Examples of nano-carrier platforms used to assist in the co-delivery of drugs for CRC therapy include liposomes, polymers, micelles, dendrimers, silica, nano-emulsion, nano-tubes and nano-gels. 119 These types of NPs, especially polymeric NPs, have the advantage of protecting PS drugs from chemical and enzymatic degradation in the gastrointestinal tract and therefore increase their stability and absorption across the intestinal epithelium with controlled drug release. 117, 120 Various studies have been conducted investigating the effective drug delivery of PS to CRC and CCSCs utilizing nano-drug carriers ( Table 3 ).
Active targeting of CRC and CRC stem cells
To improve uptake of PSs in CRC and CCS cells, active targeting has also been developed. This involves a PS that is directly delivered to the target site using specific ligands or antibodies which bind to overexpressed CRC cell receptors 7,100,131 ( Figure 6) .
Recently, several active drug-carrying and cellular target systems have been investigated (Table 4 ). Most PS drug constructs consist of PS drug conjugations to nanocarriers which are further functionalized with monoclonal antibodies (mAbs), antibody constructs or small-molecule inhibitors. These are specifically directed Meta-tetra (hydroxyphenyl) chlorine (mTHPC)
In CRC cell lines Colo-201 and PDT, phototoxicity was noted, PS localized in the liposomes and apoptotic cell death was induced Leung et al. 104 Lysosome localizing chlorin e 6 (Ce6) ATX-S10Na(II)
In 6 . Common proteins that are overexpressed in CRC cells that are possible targets for drug treatment. They include epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), epithelial cell-adhesion molecule (EpCAM), carbonic anhydrase IX (CA IX), peroxisome proliferator-activated receptor γ (PPARγ), cyclooxygenase-2 (COX-2), as well as cluster of differentiation 44, 133, 166 and 24 (CD44+, CD 133+, CD166+ and CD24+). 13, 132, 133 Additionally, technologies such as antibody or NP PEGylation, polysialylation and albumin inclusion have been used to engineer specific active targeting PS drugs. 132 Figure 5 also indicates examples of monoclonal antibodies (mAbs) and antibody constructs that are directed against CCSC-specific surface molecules. These include CD44+, CD47+, CD123+, EpCAM, ganglioside receptor 2 (GD2), leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5), insulin-like growth factor I receptor (IGF-IR), delta-like ligand 4 (Dll4), frizzled (FZD) and epiregulin (EREG) receptors. 7, 134 These surface molecules have the potential to be utilized as active targeting sites for specific PS drug delivery mechanisms in CCSCs and overall PDT enhancement in possibly preventing secondary CRC metastasis. Verteporfin succinimidyl ester Single-chain variable fragments (scFvs), antibody fragments Photoimmune conjugate retained photophysical functionality and drug delivery mechanism was more potent than free PS. In in vitro and in vivo PDT applications, it effectively killed tumour LoVo (CEA+, HER2−) cells Bhatti et al. 135 Chlorin e6 (Ce6) Site-specific immune conjugates (murine monoclonal antibody 17.1A) which recognize antigen expressed in HT-29CRC cells Photoimmune conjugate had cationic electric charge which enhanced PS delivery and showed a 90% phototoxic effect in vitro Del Governatore et al. 136 Chlorin e6 (Ce6) Phototoxic DNA aptamers were bound to unique short O-glycan-peptide signatures on HT-29CRC cells surfaces Molecular conjugate reported more than a 500-fold increase in toxicity in PDT, with no cytotoxicity noted in control groups Ferreira et al. 137 Meso-tetraphenyl chlorin disulfonate (TPCS2a) IM7-saporin (immunotoxin targeting CD44 receptor towards WiDr CRC) was transported into cells with the use of photochemical internalization (PCI) PDT treatment with drug carrier resulted in cytotoxic response with a 90% reduction in cell viability Bostad et al. 138 
5-Fluorouracil
Eudragit S100 coated citrus pectin nano-particles Citrus pectin is overexpressed in CRC cells and acts as a ligand for galectin-3 receptors. Eudragit S100 is a pH-responsive enteric polymer. Specific site delivery was observed in in vitro and in vivo studies with controlled drug delivery observed only at target sites and showed enhanced PDT cytotoxic effects at CRC and CCS cell surface receptors or target key components of the intrinsic signalling pathways of the cells. 146
Conclusion
Tumour reoccurrence and metastasis is still a major concern among CRC patients. The search for alternative therapies to increase therapeutic effect and target cancer cells directly, as well as eliminate CSCs, is well underway. PDT offers a less invasive and targeted form of therapy against cancer. How to maximally accumulate drug at tumour sites and be able to eliminate CCSs is still the main challenge among PDT researchers. Numerous studies highlighted within this review have shown the effectiveness of active TPDT in CRC to improve tumour uptake of PSs. Photosynthetic drugs are directly delivered to target sites using nano-platforms bound to specific ligands or antibodies which target overexpressed CRC cell receptors, with limited toxicity to normal tissues. This review has identified limits in the use of active TPDT mechanisms to enhance PS tumour uptake in CCSCs. Hence, PDT active drug delivery systems that specifically target overexpressed proteins in CCSCs need to be investigated in order to treat and prevent secondary metastasis. These PS drug delivery systems will need to be able to be effectively retained in CCSCs, evade immune system components, target both CRC and CCSCs as well as be released when maximum accumulation in target cells is acquired.
Unfortunately, current PDT treatments for CRC use high doses of phototoxic drugs which result in adverse effects to the patient. Therefore, it is necessary to develop new photosynthetic nano-medicines with multifunctional characters that bring together different chemotherapeutic agents that would allow double or triple therapies with lower systemic doses and significantly reduce undesirable side effects. Studies by Shams et al. 130 have proposed the principle for the use of TPDT as an adjuvant therapy for enhancement of antitumour immunity that may be capable of controlling distant disease through the active targeting of receptors that are overexpressed in CSCs. Currently, in spite of studies evaluating treatment methods targeting CCSCs, all strategies involving PDT treatment are under-test theories. Studies published so far are only beginning to investigate the ways to overcome CCSCs' resistance to PDT, and therefore, studies need to be considered evaluating combinative TPDT regimes that could effectively control CRC metastatic tumour growth and reoccurrence by eliminating CCSCs.
The evidence from this review has suggested that an active TPDT-enhanced PS drug delivery system might be a comprehensive strategy to improve CRC treatments, for example, designing an NP which is conjugated to three crucial elements: (1) a molecule for targeting specific CCSC, (2) a PS drug to eliminate CRC and (3) a chemosensitizer to overcome drug resistance. Such a combination would exert the anti-tumour TPDT effect with fewer side effects.
However, the identification of strategies that exploit the unique characteristics of CSCs requires further study and the cooperation of multidisciplinary areas in order to enhance the overall PDT treatment modality for CCSCs.
